ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Beam Therapeutics (BEAM) pipeline and stated timing

Name in SEC filings: Beam Therapeutics Inc.

Pipeline at a glance

ProgramEventStageStated timingFiling
BEAM-301/data readoutStage not stated202610-Q ·
BEAM-302Topline/data readoutStage not stated2026EX-99.1 ·
risto-celTopline/data readoutStage not statedyear-end 202610-Q ·

Source: ORION, orionbiotechai.com/company/BEAM, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/BEAM

Nearest upcoming stated timing: BEAM-301 · Topline/data readout · 2026

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
BEAM-301Clinical results2026
“initial data from the trial in 2026”

Filed · 10-Q

Still within period

As of Oct 19, 2026

risto-celClinical resultsyear-end 2026
“We expect to report updated data for the BEACON clinical trial by year-end 2026”

Filed · 10-Q

Still within period

As of Oct 19, 2026

BEAM-302Clinical results2026
“updated BEAM-302 data at a medical congress in 2026”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

BEAM-301Clinical results2026
“BEAM-301 in a Phase 1/2 clinical trial, and expect to report initial clinical data in 2026”

Filed · 10-K

Still within period

As of Oct 19, 2026

BEAM-301Clinical results2025
“data anticipated in 2025”

Filed · EX-99.1

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Retained company announcements

Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.

Historical catalog checked .

BEACON Phase 1/2 initial clinical data

2024 milestones: BEAM-101 first clinical data

Source published · Original announcement

Retained timing label: Second half of 2024

Retained summary: Beam expected initial data from multiple BEACON participants in the second half of 2024.

Retained source and collection times
Event effective
UNAVAILABLE
ORION first seen
ORION ingested

ASH abstracts: first BEAM-101 clinical data

Source published · Original announcement

Retained summary: Beam released initial BEACON findings with accepted ASH abstracts. The preliminary data used a July 2 cutoff. The release also described a patient death judged likely related to conditioning and unrelated to BEAM-101; readers should review the full safety context.

Retained source and collection times
Event effective
ORION first seen
ORION ingested

ASH announcement: updated BEACON data

Source published · Original announcement

Retained summary: Beam announced updated BEACON data using an October 28 cutoff, including seven treated participants in the analysis. This was an additional disclosure after the November abstract, not a second initial-data promise.

Retained source and collection times
Event effective
ORION first seen
ORION ingested

Read the retained source trail

Selected registry record

BEAM-302 · NCT06389877

Condition in the selected registry record
Alpha 1-Antitrypsin Deficiency
Phase in the selected registry record
Phase 1 / Phase 2
Identity checked

Original ClinicalTrials.gov record · Open the selected study

Retained company–study identity sources

Scope of retained company and registry evidence

These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.

Coverage and identity checks

Watch BEAM

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for BEAM. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See BEAM in the calendar · Review labels and methodology

Topline results are the main summary results of a clinical trial, released before the full data.